Study Information

Title: Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma External
Status: Recruiting participants
Conditions: Recurrent Adult Hodgkin Lymphoma; Recurrent Childhood Hodgkin Lymphoma; Refractory Childhood Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin; Drug: Gemcitabine Hydrochloride; Other: Laboratory Biomarker Analysis
Institutions: Dana-Farber Cancer Institute
Health Topics: Hodgkin Lymphoma

Contact Information


Dana-Farber Cancer Institute
Boston, MA 02115